M&T Bank Corp Sells 29,194 Shares of Edwards Lifesciences Co. (NYSE:EW)

M&T Bank Corp reduced its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 28.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 71,727 shares of the medical research company's stock after selling 29,194 shares during the period. M&T Bank Corp's holdings in Edwards Lifesciences were worth $5,470,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Edwards Lifesciences by 0.6% during the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company's stock worth $3,577,163,000 after acquiring an additional 325,808 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Edwards Lifesciences by 9.2% in the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company's stock valued at $1,138,575,000 after acquiring an additional 1,390,427 shares during the last quarter. Northern Trust Corp increased its position in shares of Edwards Lifesciences by 3.9% in the third quarter. Northern Trust Corp now owns 6,357,473 shares of the medical research company's stock valued at $440,446,000 after acquiring an additional 241,347 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its position in shares of Edwards Lifesciences by 16.8% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,100,000 shares of the medical research company's stock valued at $312,625,000 after acquiring an additional 590,000 shares during the last quarter. Finally, Ownership Capital B.V. increased its position in shares of Edwards Lifesciences by 21.3% in the fourth quarter. Ownership Capital B.V. now owns 3,489,915 shares of the medical research company's stock valued at $266,106,000 after acquiring an additional 613,817 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on EW shares. Oppenheimer lifted their target price on Edwards Lifesciences from $93.00 to $100.00 and gave the company an "outperform" rating in a research report on Monday, March 18th. Barclays boosted their price target on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an "overweight" rating in a research report on Tuesday. StockNews.com raised Edwards Lifesciences from a "hold" rating to a "buy" rating in a research report on Monday, April 29th. Citigroup boosted their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 3rd. Finally, Wells Fargo & Company boosted their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an "overweight" rating in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $93.27.

Edwards Lifesciences Price Performance

Shares of EW stock traded up $0.76 during trading on Tuesday, hitting $85.85. The company had a trading volume of 1,836,259 shares, compared to its average volume of 3,735,495. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The firm has a market capitalization of $51.73 billion, a P/E ratio of 37.00, a price-to-earnings-growth ratio of 3.59 and a beta of 1.10. The stock's 50-day moving average price is $90.05 and its 200 day moving average price is $79.69. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to analysts' expectations of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. Equities analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian bought 580 shares of the business's stock in a transaction on Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the purchase, the chief executive officer now directly owns 3,268 shares of the company's stock, valued at $280,198.32. The acquisition was disclosed in a filing with the SEC, which is available at this link. In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the company's stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares in the company, valued at $2,980,774.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bernard J. Zovighian bought 580 shares of the business's stock in a transaction on Monday, May 6th. The shares were acquired at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now directly owns 3,268 shares of the company's stock, valued at $280,198.32. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 237,749 shares of company stock worth $20,920,934. Company insiders own 1.27% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.